Vajdy et al., 2006 - Google Patents
Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responsesVajdy et al., 2006
View PDF- Document ID
- 4559910640044782922
- Author
- Vajdy M
- Selby M
- Medina-Selby A
- Coit D
- Hall J
- Tandeske L
- Chien D
- Hu C
- Rosa D
- Singh M
- Kazzaz J
- Nguyen S
- Coates S
- Ng P
- Abrignani S
- Lin Y
- Houghton M
- O'Hagan D
- Publication year
- Publication venue
- Journal of general virology
External Links
Snippet
Although approximately 3% of the world's population is infected with Hepatitis C virus (HCV), there is no prophylactic vaccine available. This study reports the design, cloning and purification of a single polyprotein comprising the HCV core protein and non-structural …
- 241000711549 Hepacivirus C 0 title abstract description 101
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses positive-sense
- C12N2770/00011—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses positive-sense ssRNA Viruses positive-sense
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses positive-sense
- C12N2770/00011—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses positive-sense ssRNA Viruses positive-sense
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Vajdy et al. | Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses | |
| Liang | Current progress in development of hepatitis C virus vaccines | |
| Lechmann et al. | Vaccine development for hepatitis C | |
| US20090098153A1 (en) | Activation of HCV-specific T cells | |
| O’Hagan et al. | Cationic microparticles are a potent delivery system for a HCV DNA vaccine | |
| US20110159039A1 (en) | Eliciting hcv-specific antibodies | |
| US7557199B2 (en) | Hepatitis C virus vaccine | |
| Zingaretti et al. | Why is it so difficult to develop a hepatitis C virus preventive vaccine? | |
| Lin et al. | Induction of broad CD4+ and CD8+ T-cell responses and cross-neutralizing antibodies against hepatitis C virus by vaccination with Th1-adjuvanted polypeptides followed by defective alphaviral particles expressing envelope glycoproteins gpE1 and gpE2 and nonstructural proteins 3, 4, and 5 | |
| Hunziker et al. | Perspectives: towards a peptide-based vaccine against hepatitis C virus | |
| Guo et al. | Hepatitis C virus infection and vaccine development | |
| Vidalin et al. | Use of conventional or replicating nucleic acid-based vaccines and recombinant Semliki forest virus-derived particles for the induction of immune responses against hepatitis C virus core and E2 antigens | |
| US20100291134A1 (en) | Truncated hepatitis c virus ns5 domain and fusion proteins comprising same | |
| Inchauspé et al. | Development of a hepatitis C virus vaccine | |
| US20110150911A1 (en) | Methods and reagents for treating, preventing and diagnosing bunyavirus infection | |
| AU2003248818A1 (en) | Hcv fusion proteins with modified ns3 domains | |
| Torresi et al. | Neutralising antibody, CTL and dendritic cell responses to hepatitis C virus: a preventative vaccine strategy | |
| Zhu et al. | A candidate DNA vaccine elicits HCV specific humoral and cellular immune responses | |
| Lee et al. | Hepatitis C virus envelope DNA-based immunization elicits humoral and cellular immune responses | |
| Brinster et al. | DNA vaccines for hepatitis C virus | |
| US20110177110A1 (en) | Compositions comprising cationic microparticles and hcv e1e2 dna and methods of use thereof | |
| US20050074465A1 (en) | HCV fusion proteins with modified NS3 domains | |
| Leroux-Roels | Development of prophylactic and therapeutic vaccines against hepatitis C virus | |
| Li et al. | Elicitation of strong immune responses by a DNA vaccine expressing a secreted form of hepatitis C virus envelope protein E2 in murine and porcine animal models | |
| EP1576125A2 (en) | Activation of hcv-specific cells |